Elemental impurity testing measures trace metals and catalysts left behind in a drug substance or product, most often from raw materials, reagents, or manufacturing equipment, and confirms those levels stay under the limits set by ICH Q3D and USP. It matters because unlike a synthesis impurity you can sometimes design out, elemental impurities usually have to be measured and controlled rather than eliminated entirely.
If you are building out a CMC package for a new drug substance, you have probably already run into the ICH Q3D risk assessment requirement and realized it is not a box to check once and forget. It has to reflect your actual manufacturing process, your actual raw materials, and your actual container closure system, and it has to hold up if a regulator asks why your risk assessment concluded what it concluded.
What Counts as an Impurity in a Drug Product
Impurity covers more ground than most people expect going in. There are elemental impurities (metals and catalysts), residual solvents left over from synthesis or purification, organic impurities and degradation products that form during synthesis or storage, and in some cases impurities introduced by packaging or container closure systems. Each category has its own testing approach, its own regulatory guidance, and its own acceptable limits, and a testing program that treats them as one undifferentiated bucket is going to miss things.
This is part of why impurity analysis works best as a coordinated program rather than a single assay ordered whenever a question comes up. The elemental impurity picture, the residual solvent picture, and the organic impurity picture all inform each other, and a lab that only ever sees one piece of your data at a time is going to give you a narrower answer than you actually need.
Elemental Impurities and Why ICH Q3D Changed the Testing Landscape
Before ICH Q3D, elemental impurity control leaned heavily on heavy metals testing methods that were, frankly, not very sensitive and not very specific about which metals actually mattered for a given route of administration. ICH Q3D replaced that with a risk-based framework: identify which elements are plausible contaminants given your specific synthesis route, raw materials, and equipment, assess the actual risk each one poses at your product’s permitted daily exposure level, and only then decide which ones need routine testing and at what limit.
That risk assessment is the part sponsors sometimes underestimate. It is not a formality that gets attached to a filing. Method development and validation per USP <231>, <232>, and ICH Q3D has to demonstrate the assay can actually detect the relevant elements at the levels that matter for your specific product and route of administration, which means the risk assessment and the analytical method have to be built together, not handed off separately to different teams.
Residual Solvents and Organic Impurities: The Other Side of the Impurity Profile
Elemental impurities get a lot of attention because ICH Q3D reshaped how the industry approaches them, but residual solvents and organic impurities are just as capable of holding up a filing. Residual solvent testing confirms that solvents used during synthesis or purification, methanol, acetonitrile, and similar compounds among them, are cleared to acceptable limits before the drug substance moves forward. Organic impurity and degradation product testing tracks what forms during synthesis itself and what forms over time in storage, which is a different question from what your raw materials brought in.
Both of these connect directly to the broader analytical work a program depends on. A lab running analytical development for your program already has the method development experience, and often the reference standards, to build impurity methods that are specific to your actual synthesis route rather than generic compendial methods that may not resolve your particular impurity profile.
Why Risk Assessments Matter as Much as the Assay Itself
A risk assessment that was clearly written to justify a predetermined testing plan, rather than one that actually interrogated the manufacturing process, is one of the more common reasons an impurity data package draws questions during review. The assessment has to account for catalysts used in synthesis, metals introduced by equipment and manufacturing aids, and any elements plausibly present in raw materials sourced from a specific supplier, not just the elements a generic template happens to list.
This is one more reason impurity testing benefits from sitting close to raw material testing rather than being run as a completely separate workstream. Raw material data is often the first real signal of which elements are worth worrying about for a given synthesis route, and a lab that runs both under one quality system can connect that signal to the impurity risk assessment instead of starting the risk assessment from a blank page.
How This Shows Up in a Regulatory Submission
Impurity data does not sit in an appendix. It runs through the CMC section of a submission, and reviewers tend to look closely at whether the elemental impurity risk assessment, the residual solvent data, and the organic impurity and degradation profile all tell a consistent story about the same manufacturing process. A risk assessment that references a synthesis route different from the one actually used in manufacturing, or an impurity limit that does not match the method’s demonstrated sensitivity, is the kind of inconsistency that turns into a review question and adds months to a timeline.
Getting this right earlier rather than later also affects how much rework a change in raw material supplier or synthesis step costs later on. A risk assessment built with real analytical data behind it, rather than a generic template filled in near the filing deadline, holds up better when something in the process changes and the assessment has to be revisited.
Questions We Get Often
What is the difference between elemental impurity testing and residual solvent testing? Elemental impurity testing measures trace metals and catalysts, governed primarily by ICH Q3D and USP. Residual solvent testing measures leftover solvents from synthesis or purification. They use different analytical methods and different regulatory limits, and a complete impurity profile needs both.
Does every drug substance need a full ICH Q3D risk assessment? Yes. ICH Q3D applies to new and existing drug products, and the risk assessment has to be specific to the actual manufacturing process, raw materials, and route of administration rather than a generic industry template.
Can impurity testing be run on a raw material before it goes into manufacturing? Yes, and it often should be. Testing raw materials for likely elemental contaminants before they enter the process gives the ICH Q3D risk assessment real data to work from instead of assumptions.
How long does an elemental impurity risk assessment and testing program typically take to put together? It depends on how many synthesis steps and raw material sources are involved and how much existing data is already available. QCL’s business development team can scope a timeline once they understand your specific process and filing timeline.
Quality Chemical Laboratories has been building impurity testing programs, from ICH Q3D risk assessments through residual solvent and organic impurity methods, for pharmaceutical and biopharmaceutical clients for more than 25 years, working scientist to scientist rather than through layers of account management. To talk through your program’s specific impurity profile, request a quote, submit a sample, or reach the business development team directly at BusinessDev@qualitychemlabs.com or (910) 796-3441.